Status: Not yet recruiting
A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients
FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48 weeks QD) subcutaneous (SC) doses of PLL001 compared to placebo in subjects diagnosed with ALS.
Participants needed: 153
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: PLL TX AUSTRALIA PTY LTDUpdated: Mar 19, 2026
Eligibility criteria
Males and females ≥18 years of age at the time of informed consent. [+9]
Has dementia or significant neurological, psychiatric, systemic, or organic dise... [+10]